Deals

Neurocrine hands back 2 CNS gene therapy programs to Voyager

Neurocrine handed back two discovery-stage gene therapy programs to Voyager, although the companies’ wider CNS-focused collaboration remains on track.

James Waldron May 7, 2025 7:30am

Illustration connected puzzle pieces with the acronym MA

Concentra swoops in to purchase struggling Kronos

May 1, 2025 3:07pm

MA strategy deal block push come together form

Amicus pays Dimerix $30M for late-phase rare kidney disease drug

May 1, 2025 10:59am

Graphic image of a red thumbs down against a blue background

Investor pressures Acelyrin to exit Alumis merger and liquidate

Apr 30, 2025 10:30am

Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand

Novartis pays $800M to buy Regulus for phase 3-ready kidney drug

Apr 30, 2025 9:30am

Ferrer nabs European rights for ALS asset in €500M pact

Apr 28, 2025 2:40pm